UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,446	06/22/2006	Takahiro Ueda	5404/108	6380

757 7590 02/04/2008

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, IL 60610

EXAMINER	
KATAKAM, SUDHAKAR	

ART UNIT	PAPER NUMBER
1621	

MAIL DATE	DELIVERY MODE
02/04/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/541,446	UEDA ET AL.	
	Examiner	Art Unit	
	Sudhakar Katakam	1621	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *05 July 2005*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-19* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1-19* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☒ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date *7/5/05,10/06/05,12/20/05*.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

Information Disclosure Statement

1. The examiner has considered applicant's Information Disclosure Statements of 7/5/07, 10/6/05 and 12/20/05. Please refer to the signed copies of the PTO-1449 forms attached herewith.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

3. The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

4. Claims 1-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over **Merck & Co., Inc** (GB 947,643) and applicants' acknowledged prior art in view of **Kijima et al** (US 4,061,660), **Kijima et al** (US 4,039,573) and **Morita et al** (US 4,163,864).

Merck & Co teaches preparation and purification of reduced coenzyme Q_{10} from the oxidized form of coenzyme Q_{10} in ethanol and adding excess of sodium borohydride in aqueous medium and the resulted yellow orange compound is diluted with water and the compound is extracted with petroleum ether. The petroleum extracts are washed with water and then dried, which results in crystallized form of reduced coenzyme Q_{10}, the pure hydroquinone of coenzyme Q_{10}. This may be recrystallized from alcohol-petroleum ether mixture.

Applicants' specification acknowledges the impurities present in the reduced coenzyme Q_{10} such as oxidized coenzyme Q_{10}, reducing agents such as sodium borohydride, and known reducing agents such as zinc and vitamin C species [see page 1 of the specification].

The difference between the instant claims and the **Merck & Co** is that in the instant claims comprises washing crystals with water-soluble organic solvents and thereby remove a water-soluble impurities from the crystals, whereas **Merck & Co** teaches washing petroleum extract with water and then dried to get the pure crystals.

Washing and purifying crystals is a well known process in the art. It is desirable to use suitable solvents in which impurities get dissolved. **Merck & Co** is silent on the applicants' solvents; however it is a common practice to use suitable solvents in washing/purifying the crystals. For example, in the analogous situation of purification of similar compounds, the crystals are washed with water soluble organic solvents. **Kijima et al** (US 4,061,660) teach washing of crystals with diethyl ether [see Example 1]. **Kijima et al** (US 4,039,573) additionally discloses an analogous washing process

where zinc is the catalyst [see Example 3]. **Morita et al** (US 4,163,864) also shows an analogous washing process, where methanol is used for washing [see Example 1].

In summary, **Merck & Co** teaches preparation and purification of reduced coenzyme Q_{10} from the oxidized form of coenzyme Q_{10} in ethanol and adding excess of sodium borohydride. Applicants' specification acknowledges the impurities present in the reduced coenzyme Q_{10}. An analogous prior art teaches the use of water soluble organic solvents in washing the crystals to remove the impurities.

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention was made to start with the **Merck and Co** teachings and combine the teachings of known solvents for the purification process, to achieve the instant claims with a reasonable expectation success. It is after all a simple washing to remove impurities using suitable solvents. The selection a solvent is depends on the solubility of the impurities.

Modifying such parameters is prima facie obvious because an ordinary artisan would be motivated to optimize the purification process to make the process more economical, since it is within the scope to exchange the solvents through a routine experimentation.

Conclusion

5. No Claim is allowed.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhakar Katakam whose telephone number is 571-272-9929. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on 571-272-0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Sudhakar Katakam
Patent Examiner
1st Feb 2008

PETER O'SULLIVAN
PRIMARY EXAMINER
GROUP 1600